1. Outcome of BCG Vaccination in ADA-SCID Patients: A 12-Patient Series
- Author
-
Daniele Canarutto, Chiara Oltolini, Federica Barzaghi, Valeria Calbi, Maddalena Migliavacca, Francesca Tucci, Vera Gallo, Giulia Consiglieri, Francesca Ferrua, Salvatore Recupero, Maria Celia Cervi, Hamoud Al-Mousa, Anna Pituch-Noworolska, Chiara Tassan Din, Paolo Scarpellini, Paolo Silvani, Claudia Fossati, Miriam Casiraghi, Daniela Maria Cirillo, Antonella Castagna, Maria Ester Bernardo, Alessandro Aiuti, and Maria Pia Cicalese
- Subjects
enzyme replacement therapy ,isoniazid ,rifampin ,tuberculosis ,newborn screening ,gene therapy ,Biology (General) ,QH301-705.5 - Abstract
Vaccination with Bacillus Calmette–Guérin (BCG) can be harmful to patients with combined primary immunodeficiencies. We report the outcome of BCG vaccination in a series of twelve patients affected by adenosine deaminase deficiency (ADA-SCID). BCG vaccination resulted in a very high incidence of complications due to uncontrolled replication of the mycobacterium. All patients who developed BCG-related disease were treated successfully and remained free from recurrence of disease. We recommend the prompt initiation of enzyme replacement therapy and secondary prophylaxis to reduce the risk of BCG-related complications in ADA-SCID patients.
- Published
- 2023
- Full Text
- View/download PDF